JN
Therapeutic Areas
Vir Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tocilizumab | Chronic Hepatitis Delta (CHD) | Phase 3 |
| VIR-2218 + VIR-3434 | Chronic Hepatitis B (CHB) | Phase 2 |
| VIR-2482 | Seasonal Influenza Prophylaxis | Phase 2 |
| VIR-2986 | Chronic Hepatitis Delta (CHD) | Phase 1 |
| VIR-5500 (AMG 509) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 |
| Sotrovimab | COVID-19 | Authorized |
| Ebanga™ (Ansuvimab-zykl) | Ebola Virus Infection | Approved |
Leadership Team at Vir Biotechnology
MD
Marianne De Backer
President, Chief Executive Officer and Director
JC
Jeff Calcagno
Executive Vice President and Chief Business Officer
VD
Vanina de Verneuil
Executive Vice President, General Counsel and Corporate Secretary
ME
Mark Eisner
Executive Vice President and Chief Medical Officer
MH
Maninder Hora
Executive Vice President and Chief Technical Operations Officer
JO
Jason O’Byrne
Executive Vice President and Chief Financial Officer
JE
Jennifer Eileen Towne
Executive Vice President and Chief Scientific Officer
TM
Toby Medaris
Senior Vice President Human Resources
CW
Carolyn Wang
Senior Vice President Corporate Communications
AL
Antonio Lanzavecchia
Senior Vice President and Senior Research Fellow